Why Prime Medicine Stock Was Climbing Higher This Week

News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.Targeting a lung and liver disorderPrime's encouraging news came on Tuesday when the company announced it had launched a preclinical program aimed at treating alpha-1 ant ...